logo-loader
viewOpen Orphan Plc

Preferred Partner Agreement

/**/ .p{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.p{}p.ac{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt; margin-left:0cm;line-height:12.65pt}span.aa{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}p.ad{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 12.65pt; margin-bottom: 8.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 0cm; text-align: center}span.y{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.ae{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";line-height: 12.65pt; margin-bottom: 8.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 0cm; text-align: center}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}p.af{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.v{color:black} span.h{}p.ag{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.ah{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}p.ai{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.r{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.j,li.j,div.j{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.q{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.aj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}p.ak{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify} /**/
RNS Number : 8676S
Open Orphan PLC
11 November 2019
 

11 November 2019

Open Orphan plc

("Open Orphan" or the "Company")


Open Orphan signs Preferred Partner Agreement

 

Open Orphan, a European-focussed, rare and orphan drug consulting services platform company, is pleased to announce the signing of a preferred partner agreement between Open Orphan and Ipsen Group ("Ipsen").

The agreement selects Venn Life Sciences ("Venn"), which is part of the Open Orphan group, as the preferred partner for Ipsen's Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

The partnership is part of Open Orphan's strategy to transform Venn Life Sciences and is expected to be one of many long-term partnership contracts which is expected to deliver recurring revenues for the business. Open Orphan's aim is to transform Venn through restructuring the business to reduce operational leverage, increase revenue, improve operating margins and launch additional complementary services.

Cathal Friel, Chief Executive of Open Orphan commented:

"When we completed the reverse takeover of Venn earlier this summer we promised shareholders that one of our key objectives would be to transform Venn into a profitable pharma services company. This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector. I look forward to announcing more positive news in due course."

 

Enquiries:

Open Orphan plc Tel: +353 1 644 0007
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Dan Sherwen

 

Notes to Editors on Open Orphan:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of pharma services businesses across Europe. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing one of Europe's largest rare disease  genomic database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

Notes to Editors on Ipsen Group:

Ipsen is a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases.  It has a well-established and successful Consumer Healthcare business.  It is also committed to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients. 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
CNTCKFDQABDDNDK

Quick facts: Open Orphan Plc

Price: 5.775

Market: AIM
Market Cap: £14.7 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'continuing to target rapid scale-up and profitability'

Proactive Research analyst Emma Ulker says Open Orphan (LON:ORPH) is continuing to target rapid scale-up and profitability in the dynamic European orphan and rare disease consulting sector via acquisitions and organic means. The company’s Venn Life Sciences consulting arm has recently signed...

1 day, 23 hours ago